[Cerebral ischaemia: tomorrow's therapeutic tracks].
Thrombolysis remains the main therapeutic strategy used in stroke, but with a limited use to only a part of stroke patients. A neuroprotective approach would be necessary with a double objective : (1) to serve as an add-on treatment with thrombolysis to improve safety and increase therapeutic window ; (2) to limit infarct area by delaying neuronal death. While numerous molecules failed in clinical trials in stroke, pharmacological development is on-going with pleiotropic drugs targeting both neuronal and vascular parts of neurovascular unit. Another approach targets the functional rehabilitation and the neurorepair using pharmacological ways or cell therapy.
Bordet
Régis
R
EA1046, département de pharmacologie médicale, Institut de médecine prédictive et de recherche thérapeutique, Université Lille-Nord de France, Faculté de médecine, Centre hospitalier et universitaire de Lille, 2, avenue Oscar Lambret 59037 Lille Cedex, France. r-bordet@chru-lille.fr
Ouk
Thavarak
T
Onténiente
Brigitte
B
Charriaut-Marlangue
Christiane
C
Heurteaux
Catherine
C
D017209:Apoptosis; D001253:Astrocytes / Q000502:physiology; D001393:Azoles / Q000627:therapeutic use; D002545:Brain Ischemia / Q000188:drug therapy / Q000628:therapy*; D002544:Cerebral Infarction / Q000473:pathology / Q000517:prevention & control; D003937:Diagnosis, Differential; D004730:Endothelium, Vascular / Q000503:physiopathology; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D006801:Humans; D054833:Isoindoles; D009474:Neurons / Q000473:pathology / Q000502:physiology; D018696:Neuroprotective Agents / Q000627:therapeutic use; D016566:Organoselenium Compounds / Q000627:therapeutic use; D015424:Reperfusion; D009435:Synaptic Transmission / Q000502:physiology
D001393:Azoles; D054833:Isoindoles; D018696:Neuroprotective Agents; D016566:Organoselenium Compounds; D016179:Granulocyte Colony-Stimulating Factor; C042986:ebselen